X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (28) 28
cancer (19) 19
humans (19) 19
chemotherapy (16) 16
gastroenterology & hepatology (16) 16
life sciences (15) 15
survival (11) 11
oncology (10) 10
surgery (10) 10
care and treatment (9) 9
male (9) 9
middle aged (9) 9
gastroenterology and hepatology (8) 8
female (7) 7
oxaliplatin (7) 7
adult (6) 6
aged (6) 6
colorectal cancer (6) 6
health aspects (6) 6
prognosis (6) 6
antineoplastic combined chemotherapy protocols - therapeutic use (5) 5
liver metastases (5) 5
medical prognosis (5) 5
metastasis (5) 5
retrospective studies (5) 5
aged, 80 and over (4) 4
analysis (4) 4
animals (4) 4
cisplatin (4) 4
disease-free survival (4) 4
endoscopy (4) 4
fluorouracil (4) 4
hematology, oncology and palliative medicine (4) 4
immunohistochemistry (4) 4
immunotherapy (4) 4
medicine & public health (4) 4
metastases (4) 4
patients (4) 4
peritoneum (4) 4
radiation (4) 4
resection (4) 4
tumors (4) 4
[sdv]life sciences [q-bio] (3) 3
carcinoembryonic antigen (3) 3
carcinoma (3) 3
cetuximab (3) 3
cholangiocarcinoma (3) 3
colorectal-cancer (3) 3
combined modality therapy (3) 3
diagnosis (3) 3
fluorouracil - administration & dosage (3) 3
gastroenterology (3) 3
hepatocholangiocarcinoma (3) 3
intraperitoneal chemotherapy (3) 3
irinotecan (3) 3
leucovorin (3) 3
liver (3) 3
liver-transplantation (3) 3
mesothelioma (3) 3
open-label (3) 3
pancreatic neoplasms - pathology (3) 3
patient outcomes (3) 3
radiotherapy (3) 3
research (3) 3
survival rate (3) 3
systemic chemotherapy (3) 3
treatment outcome (3) 3
usage (3) 3
young adult (3) 3
1st-line treatment (2) 2
[ sdv.can ] life sciences [q-bio]/cancer (2) 2
[sdv.can]life sciences [q-bio]/cancer (2) 2
[sdv.mp.bac]life sciences [q-bio]/microbiology and parasitology/bacteriology (2) 2
adolescent (2) 2
antineoplastic combined chemotherapy protocols - adverse effects (2) 2
bacteriology (2) 2
bevacizumab (2) 2
biochemistry, molecular biology (2) 2
biomarkers, tumor - metabolism (2) 2
breast-cancer (2) 2
case report (2) 2
case reports (2) 2
cell line, tumor (2) 2
cisplatin - administration & dosage (2) 2
colon - pathology (2) 2
colon cancer (2) 2
colonic cancer (2) 2
colonic neoplasms - pathology (2) 2
colorectal neoplasms - pathology (2) 2
colorectal neoplasms - therapy (2) 2
combination (2) 2
constipation (2) 2
cytoreductive surgery (2) 2
defective adenoviral vectors (2) 2
development and progression (2) 2
endoscopic treatment (2) 2
epidemiology (2) 2
esophageal metastasis (2) 2
fluorouracil - therapeutic use (2) 2
follow-up studies (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Expert opinion on biological therapy, ISSN 1471-2598, 01/2020
Colorectal cancer (CRC) is one of the most frequent and lethal cancers in the world, and therapies are still insufficient. Immune checkpoint inhibitors (ICI)... 
Journal Article
International Journal of Colorectal Disease, ISSN 0179-1958, 1/2019, Volume 34, Issue 1, pp. 169 - 175
Journal Article
Frontiers in Immunology, ISSN 1664-3224, 01/2020, Volume 10
Because of a loss-of-function mutation in the GGTA1 gene, humans are unable to synthetize α1,3-Galactose (Gal) decorated glycans and develop high levels of... 
enterobacteriaceae | α1,3-Galactosyltransferase | α1,3-Gal antigen | shotgun data | intestinal microbiome
Journal Article
Digestive and Liver Disease, ISSN 1590-8658, 2013, Volume 46, Issue 2, pp. 105 - 112
Journal Article
European Journal of Cancer, ISSN 0959-8049, 04/2019, Volume 111, pp. 94 - 106
Journal Article
Bulletin du Cancer, ISSN 0007-4551, 11/2018, Volume 105, Issue 11, pp. 1033 - 1041
Recently, the emergence of anti-CTLA-4 and anti-PD-1/PD-L1 antibodies called immune check-point inhibitors (ICPI) has modified the landscape of anti-cancer... 
Anti-Pd-1 | Mechanisms | Toxicity | Immunotherapy | Anti-Ctla-4 | Physiopathology
Journal Article
World journal of gastroenterology, ISSN 1007-9327, 02/2018, Volume 24, Issue 7, pp. 870 - 875
Hepatocholangiocarcinoma (cHCC-ICC) is a rare primary hepatic tumor defined by the presence of histological features of both hepatocellular carcinoma (HCC) and... 
Hepatocholangiocarcinoma | Chemotherapy | Esophageal metastasis | Gemcitabine plus platinum-based chemotherapy | Stem cell-subtype | Case Report
Journal Article
Annals of Surgical Oncology, ISSN 1068-9265, 10/2018, Volume 25, Issue 11, pp. 3271 - 3279
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2015, Volume 33, Issue 15_suppl, pp. e22128 - e22128
Journal Article
Clinical Case Reports, ISSN 2050-0904, 09/2019, Volume 7, Issue 9, pp. 1689 - 1693
Nivolumab may induce severe celiac‐like enteropathy, that may appear very rapidly, after only two injections of nivolumab, and may be successfully treated with... 
immune‐related adverse effects | nivolumab | celiac‐like enteropathy | PD‐1 inhibitors | immunotherapy | Immunoglobulins | Nutrition | Diarrhea | Parenteral nutrition | Thyroid gland | Metastasis | Family medical history | Patients | Small intestine | Inflammatory bowel disease | Atrophy | Celiac disease | Lymphocytes | Immunotherapy | Kidney cancer | Colon | Endoscopy
Journal Article
Gastroenterology, ISSN 0016-5085, 04/2015, Volume 148, Issue 4, pp. S-230 - S-230
Journal Article